Shuhang Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shuhang Wang has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Ning Li
Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 shared publications - Rongshou Zheng
National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 shared publications - Wenqiang Wei
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 shared publications - Yale Jiang
Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 shared publications - Yue Yu
Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 shared publications - Hua Bai
CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China
2 shared publications
Latest Publications
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Mobilizing China and the Global Community to Confront the Treatment Desert for Pediatric Solid Tumors
Summary: Pediatric solid tumors are distinct clinical entities that impose heavy socioeconomic burden and while their incidence has increased in recent years, treatment options are often limited, with only 27 drugs approved for pediatric solid tumors in the United States, and fewer still, 13, in China. The scale of the unmet medical need is immense and new efforts are urgently needed to develop efficient therapeutics and improve these children's lives.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mobilizing China and the Global Community to Confront the Treatment Desert for Pediatric Solid Tumors
Summary: Pediatric solid tumors are distinct clinical entities that impose heavy socioeconomic burden and while their incidence has increased in recent years, treatment options are often limited, with only 27 drugs approved for pediatric solid tumors in the United States, and fewer still, 13, in China. The scale of the unmet medical need is immense and new efforts are urgently needed to develop efficient therapeutics and improve these children's lives.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Mobilizing China and the Global Community to Confront the Treatment Desert for Pediatric Solid Tumors
Summary: Pediatric solid tumors are distinct clinical entities that impose heavy socioeconomic burden and while their incidence has increased in recent years, treatment options are often limited, with only 27 drugs approved for pediatric solid tumors in the United States, and fewer still, 13, in China. The scale of the unmet medical need is immense and new efforts are urgently needed to develop efficient therapeutics and improve these children's lives.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mobilizing China and the Global Community to Confront the Treatment Desert for Pediatric Solid Tumors
Summary: Pediatric solid tumors are distinct clinical entities that impose heavy socioeconomic burden and while their incidence has increased in recent years, treatment options are often limited, with only 27 drugs approved for pediatric solid tumors in the United States, and fewer still, 13, in China. The scale of the unmet medical need is immense and new efforts are urgently needed to develop efficient therapeutics and improve these children's lives.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables and Figure from Mobilizing China and the Global Community to Confront the Treatment Desert for Pediatric Solid Tumors
Supplementary tables - Table S1. Incidence and survival rates for childhood cancers in China, 2014 -2018+ - Table S2. Drugs approved for pediatric solid tumors by FDA - Table 3. Drugs officially approved for pediatric solid tumors by NMPA in China Supplementary figure - Supplement Figure S1. The distribution of incidence divided by cancer types during 2014-2018 in China
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables and Figure from Mobilizing China and the Global Community to Confront the Treatment Desert for Pediatric Solid Tumors
Supplementary tables - Table S1. Incidence and survival rates for childhood cancers in China, 2014 -2018+ - Table S2. Drugs approved for pediatric solid tumors by FDA - Table 3. Drugs officially approved for pediatric solid tumors by NMPA in China Supplementary figure - Supplement Figure S1. The distribution of incidence divided by cancer types during 2014-2018 in China
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables and Figure from Mobilizing China and the Global Community to Confront the Treatment Desert for Pediatric Solid Tumors
Supplementary tables - Table S1. Incidence and survival rates for childhood cancers in China, 2014 -2018+ - Table S2. Drugs approved for pediatric solid tumors by FDA - Table 3. Drugs officially approved for pediatric solid tumors by NMPA in China Supplementary figure - Supplement Figure S1. The distribution of incidence divided by cancer types during 2014-2018 in China
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables and Figure from Mobilizing China and the Global Community to Confront the Treatment Desert for Pediatric Solid Tumors
Supplementary tables - Table S1. Incidence and survival rates for childhood cancers in China, 2014 -2018+ - Table S2. Drugs approved for pediatric solid tumors by FDA - Table 3. Drugs officially approved for pediatric solid tumors by NMPA in China Supplementary figure - Supplement Figure S1. The distribution of incidence divided by cancer types during 2014-2018 in China
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (1) , 26-29
Mobilizing China and the Global Community to Confront the Treatment Desert for Pediatric Solid Tumors
Summary: Pediatric solid tumors are distinct clinical entities that impose heavy socioeconomic burden and while their incidence has increased in recent years, treatment options are often limited, with only 27 drugs approved for pediatric solid tumors in the United States, and fewer still, 13, in China. The scale of the unmet medical need is immense and new efforts are urgently needed to develop efficient therapeutics and improve these children's lives.
- 12 January 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (1) , 26-29
Open AccessMobilizing China and the Global Community to Confront the Treatment Desert for Pediatric Solid Tumors
Summary: Pediatric solid tumors are distinct clinical entities that impose heavy socioeconomic burden and while their incidence has increased in recent years, treatment options are often limited, with only 27 drugs approved for pediatric solid tumors in the United States, and fewer still, 13, in China. The scale of the unmet medical need is immense and new efforts are urgently needed to develop efficient therapeutics and improve these children's lives.
- Open Access
- 4 April 2022
- Published by SPIE-Intl Soc Optical Eng
- p. 43
A generative adversarial network for ultrasound signal enhancement by transforming low-voltage beamformed radio frequency data to high-voltage data
SPIE Digital Library Proceedings
- 4 April 2022
- Published by SPIE-Intl Soc Optical Eng
- p. 43
Open AccessA generative adversarial network for ultrasound signal enhancement by transforming low-voltage beamformed radio frequency data to high-voltage data
SPIE Digital Library Proceedings
- Open Access
- 22 February 2022
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 24, 799-813
Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials
- 22 February 2022
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 24, 799-813
Open AccessLandscape and perspectives of macrophage -targeted cancer therapy in clinical trials
- 30 September 2020
- Published by Springer Nature in European Radiology
- Vol. 31 (4) , 2332-2339
Missed rib fractures on initial chest CT in trauma patients: time patterns, clinical and forensic significance
Objective To analyze missed rib fractures and proper time for evaluation on CT at different ages and to determine factors that favor missed fractures. Methods One hundred patients with rib fractures who underwent CT were classified into three groups according to their age: young, middle-aged, and elderly. CT was performed within 1 to 6 weeks after trauma. The imaging features and temporal changes of rib fractures were analyzed. Results At the first CT during the initial week, 638 ribs were detected with one or several fractures, overall 838 fractures were confirmed, and 6 were suspected. In the next 2–6 weeks, 47 occult rib fractures were additionally detected. The number of additionally diagnosed fractures was the highest in respectively the 3rd week among younger, 4th week in the middle-aged, and 6th week in the elderly groups. The detection of occult rib fractures was significantly delayed in the middle-aged and elderly groups compared with the young group (p < 0.05). The time to form bony callus was also significantly (p < 0.05) delayed with age, with significantly (p < 0.05) more time needed to form bony callus in the middle-aged (23.8 ± 4.5 days) and elderly (28.48 ± 5.1 days) groups than in the young group (18.0 ± 2.2 days). Conclusions Most rib fractures can be detected within the first week after trauma. Detection of occult rib fractures will be delayed with increase of age, and repeated CT scanning should be appropriately postponed in patients at different ages. Trabecula, inner and outer plates, costal angle, and cartilage are the primary locations for occult and subtle fractures which should be carefully evaluated. Key Points • More rib fractures can be detected on repeated CT scans, especially for subtle and occult rib fractures. • Detection of all rib fractures helps relieve the patient’s concerns and determine the degree of personal injury for appropriate evaluation.
- 30 September 2020
- Published by Springer Nature in European Radiology
- Vol. 31 (4) , 2332-2339
Missed rib fractures on initial chest CT in trauma patients: time patterns, clinical and forensic significance
Objective To analyze missed rib fractures and proper time for evaluation on CT at different ages and to determine factors that favor missed fractures. Methods One hundred patients with rib fractures who underwent CT were classified into three groups according to their age: young, middle-aged, and elderly. CT was performed within 1 to 6 weeks after trauma. The imaging features and temporal changes of rib fractures were analyzed. Results At the first CT during the initial week, 638 ribs were detected with one or several fractures, overall 838 fractures were confirmed, and 6 were suspected. In the next 2–6 weeks, 47 occult rib fractures were additionally detected. The number of additionally diagnosed fractures was the highest in respectively the 3rd week among younger, 4th week in the middle-aged, and 6th week in the elderly groups. The detection of occult rib fractures was significantly delayed in the middle-aged and elderly groups compared with the young group (p < 0.05). The time to form bony callus was also significantly (p < 0.05) delayed with age, with significantly (p < 0.05) more time needed to form bony callus in the middle-aged (23.8 ± 4.5 days) and elderly (28.48 ± 5.1 days) groups than in the young group (18.0 ± 2.2 days). Conclusions Most rib fractures can be detected within the first week after trauma. Detection of occult rib fractures will be delayed with increase of age, and repeated CT scanning should be appropriately postponed in patients at different ages. Trabecula, inner and outer plates, costal angle, and cartilage are the primary locations for occult and subtle fractures which should be carefully evaluated. Key Points • More rib fractures can be detected on repeated CT scans, especially for subtle and occult rib fractures. • Detection of all rib fractures helps relieve the patient’s concerns and determine the degree of personal injury for appropriate evaluation.
- Open Access
- 9 April 2020
- Published by Elsevier in Genes & Diseases
- Vol. 9 (1) , 245-251
The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
- 9 April 2020
- Published by Elsevier in Genes & Diseases
- Vol. 9 (1) , 245-251
Open AccessThe role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
- 1 September 2019
- Published by Elsevier in Lung Cancer
- Vol. 135, 116-122
Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung
- 1 September 2019
- Published by Elsevier in Lung Cancer
- Vol. 135, 116-122
Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung